The 36 references in paper S. Avdeev N., С. Авдеев Н. (2016) “Клинические симптомы и качество жизни пациентов с хронической обструктивной болезнью легких: субъективно оцениваемые показатели или факторы, определяющие прогноз? // Symptoms and quality of life in patients with chronic obstructive pulmonary disease: are there patient_defined outcomes or predictive factors?” / spz:neicon:pulmonology:y:2016:i:2:p:231-237

1
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2016 report is available onwww.goldcopd.com
(check this in PDF content)
2
Hogg J.C., McDonough J.E., Suzuki M. Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest. 2013; 143: 1436–1443.
(check this in PDF content)
3
Decramer M., Janssens W., Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379: 1341–1351.
(check this in PDF content)
4
Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370: 741–750.
(check this in PDF content)
5
Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD.2014; 9: 963–974.
(check this in PDF content)
6
Hoyert D.L., Xu J. Deaths: preliminary data for 2011. Natl. Vital. Stat. Rep. 2012; 61: 1–51.
(check this in PDF content)
7
Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ. 2002; 51 (SS06): 1–16.
(check this in PDF content)
8
Kessler R., Partridge M.R., Miravitlles M. et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study.Eur. Respir. J.2011; 37: 264–272.
(check this in PDF content)
9
Kim Y.J., Lee B.K., Jung C.Y. et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL study.Korean J. Intern. Med.2012; 27: 426–435.
(check this in PDF content)
10
Joshi M., Joshi A., Bartter T. Symptom burden in chronic obstructive pulmonary disease and cancer. Curr. Opin. Pulm. Med. 2012; 18: 97–103.
(check this in PDF content)
11
Bárbara C., Moita J., Cardoso J. et al. The importance of dyspnoea in the diagnosis of chronic obstructive pulmonary disease – a descriptive analysis of a stable cohort in Portugal (SAFE Trial). Rev. Port. Pneumol.2011; 17: 131–138.
(check this in PDF content)
12
Miravitlles M., Worth H., Soler Cataluña J.J. et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir. Res. 2014; 15: 122. Рис. 4. КЖ по шкале SGRQ через 12 нед. терапии у пациентов с ХОБЛ II и III стадии Примечание: шкала SGRQ является обратной: меньшая сумма баллов свидетельствует о лучшем КЖ [34, 36]. Figure 4. Change in quality of life in 12-wk treatment of patients with stage 2 to 3 COPD Notes. Less SGRQ total score corresponds to better quality of life [34, 36]. Рис. 5. Динамика одышки по шкале TDI через 12 нед. терапии у пациентов с ХОБЛ II и III стадии [34, 36] Figure 5. Change in TDI score in 12-wk treatment of patients with s
(check this in PDF content)
13
Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.
(check this in PDF content)
14
Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434–1340.
(check this in PDF content)
15
Steer J., Norman E.M., Afolabi O.A. et al. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012; 67: 117–121.
(check this in PDF content)
16
Burgel P.R., Nesme-Meyer P., Chanez P. et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009; 135: 975–982.
(check this in PDF content)
17
Watz H., Waschki B., Meyer T., Magnussen H. Physical activity in patients with COPD.Eur. Respir. J.2009; 33: 262–272.
(check this in PDF content)
18
Vaes A.W., Garcia-Aymerich J., Marott J.L. et al. Changes in physical activity and all-cause mortality in COPD. Eur. Respir. J. 2014; 44: 1199–1209.
(check this in PDF content)
19
Curtis J.R., Patrick D.L. The assessment of health status among patients with COPD. Eur. Respir. J. 2003; 21 (Suppl. 41): 36s–45s.
(check this in PDF content)
20
Reardon J.Z., Lareau S.C., ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am. J. Med. 2006; 119 (10A): S32–S37.
(check this in PDF content)
21
Beeh K.M., Beier J. The short, the long and the “ultralong”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv. Ther. 2010; 7: 150–159.
(check this in PDF content)
22
Tashkin D.P. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr. Opin. Pulm. Med.2005; 11: 121–128.
(check this in PDF content)
23
Tashkin D.P., Ferguson G.T.Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir. Res.2013; 14: 49.
(check this in PDF content)
24
Sutherland E.R., Cherniack R.M. Management of chronic obstructive pulmonary disease. N. Engl. J. Med.2004; 350: 2689–2697.
(check this in PDF content)
25
Авдеев С.Н. Выбор оптимальной терапии при ранних стадиях хронической обструктивной болезни легких. Справочник поликлинического врача.2009; 11: 27–31.
(check this in PDF content)
26
Rennard S., Decramer M., Calverley P.M. et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey.Eur. Respir. J. 2002; 20: 799–805.
(check this in PDF content)
27
Green M. How big are the bronchioles?St. Thomas Hosp. Gaz. 1965; 63: 136–139.
(check this in PDF content)
28
Pinto-Plata V.M., Celli-Cruz R.A., Vassaux C. et al. Differences in cardiopulmonary exercise test results by American Thoracic Society / European Respiratory Society – Global initiative for chronic obstructive lung disease stage categories and gender. Chest. 2007; 132; 1204–1211.
(check this in PDF content)
29
Pitta F., Troosters T., Spruit M.A. et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2005; 171: 972–977.
(check this in PDF content)
30
Tantucci C., Modina D. Lung function decline in COPD. Int. J. COPD. 2012; 7: 95–99.
(check this in PDF content)
31
Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация – новая парадигма длительно терапии хронической обструктивной болезни легких. Практическая пульмонология.2015; 3: 24–32.
(check this in PDF content)
32
Muruganandan S., Jayaram L. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. Int. J. COPD.2015; 10: 1179–1189.
(check this in PDF content)
33
Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4).Eur. Respir. J.2015; 45: 969–979.
(check this in PDF content)
34
Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109: 1312–1319.
(check this in PDF content)
35
Ferguson G.T., Flezar M., Korn S. et al. Efficacy of tiotropium/olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv. Ther. 2015; 32: 523–536.
(check this in PDF content)
36
Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo. Poster PA2958 presented at the European Respiratory Society International Congress, Amsterdam, the Netherlands,
(check this in PDF content)